- Home
- SATL vs ALLO Comparison
SATL vs ALLO Comparison
Compare SATL & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SATL | ALLO |
|---|---|---|
| Founded | 2010 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 482.3M | 539.4M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | SATL | ALLO |
|---|---|---|
| Price | $5.71 | $2.57 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 11 |
| Target Price | $5.50 | ★ $8.40 |
| AVG Volume (30 Days) | ★ 9.5M | 4.5M |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 34.09 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $68.54 | N/A |
| Revenue Next Year | $56.23 | $140,929.80 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.26 | $0.86 |
| 52 Week High | $6.84 | $2.80 |
Technical Indicators
Market Signals| Indicator | SATL | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 64.95 | 57.54 |
| Support Level | $3.18 | $2.14 |
| Resistance Level | $5.93 | $2.71 |
| Average True Range (ATR) | 0.75 | 0.24 |
| MACD | 0.20 | -0.01 |
| Stochastic Oscillator | 71.12 | 75.00 |
Price Performance
Historical ComparisonAbout SATL Satellogic Inc.
Satellogic Inc is a provider of satellite imagery to governments and commercial customers globally. It geographically operates in North America, Europe, Asia and South America. It derives maximum revenue from Asia Pacific.
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.